Clinical Trials Logo

Advanced Breast Cancer clinical trials

View clinical trials related to Advanced Breast Cancer.

Filter by:

NCT ID: NCT00546104 Completed - Clinical trials for Advanced Breast Cancer

Phase II Dasatinib Study in Advanced Breast Cancer

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if dasatinib will safely reduce the size or spread of your tumor.

NCT ID: NCT00494481 Completed - Clinical trials for Advanced Breast Cancer

E3 Breast Cancer Taxotere Combination

Start date: January 2006
Phase: Phase 2
Study type: Interventional

To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology

NCT ID: NCT00452673 Completed - Clinical trials for Advanced Breast Cancer

Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer

Start date: June 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to learn about the safety and efficacy of Dasatinib in combination with Capecitabine for patients with advanced breast cancer, and who have received treatment with a taxane and an anthracycline

NCT ID: NCT00445458 Completed - Breast Neoplasms Clinical Trials

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Start date: September 11, 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to learn whether it is safe and effective to administer HKI-272 (neratinib) in combination with paclitaxel in patients with breast cancer.

NCT ID: NCT00428220 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Start date: July 2007
Phase: N/A
Study type: Interventional

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.

NCT ID: NCT00398567 Completed - Clinical trials for Advanced Breast Cancer

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Start date: April 4, 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of HKI-272 (neratinib) in combination with trastuzumab in patients with advanced breast cancer.

NCT ID: NCT00387907 Completed - Breast Cancer Clinical Trials

Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

Start date: October 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the anti-tumor activity of the combination of experimental drug (larotaxel) when combined with Herceptin® in patients with advanced breast cancer. Anti-tumor activity will be determined by looking at changes in tumor size on CT or MRI scans. Additional goals of this study are to look at patient safety, to determine how long the study drugs (larotaxel and Herceptin®) stay in the patient's body and what effects the study medications may have on each other, and to find out how long patients remain cancer free on this study treatment.

NCT ID: NCT00328120 Completed - Clinical trials for Advanced Breast Cancer

Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

Start date: April 2004
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer

NCT ID: NCT00327769 Completed - Clinical trials for Advanced Breast Cancer

Faslodex Advanced Breast Cancer Local Chinese Study

Start date: November 2005
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.

NCT ID: NCT00322348 Completed - Clinical trials for Advanced Breast Cancer

Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate whether Zoladex 10.8 mg (12-weekly) is non-inferior to Zoladex 3.6 mg (4-weekly) in pre-menopausal women with oestrogen receptor positive advanced breast cancer by assessment of progression-free survival at 24 weeks. Secondary Objectives are to compare the safety and tolerability profile of ZOLADEX 10.8 mg and ZOLADEX 3.6 mg by assessment of adverse events (AEs)and to assess goserelin PK in Japanese and Caucasian participants who have received ZOLADEX 10.8 mg by assessment of goserelin plasma concentration time profiles Recruitment into the study has been permanently stopped as of 24 December 2007 due to slow recruitment. 98 (vs the planned 260) patients were randomised into the study and will be followed as per protocol for 2 years